Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.
The company said the revenue growth was driven by growing international demand for its noninvasive prenatal testing products and services.
The company had a profit of £3.4 million, or £0.01 per share, for the year compared to a loss of £9.6 million, or £0.03 per share, the previous year.
Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.
The company said its higher revenues were due in part to international performance including continued penetration of Middle Eastern and Asian markets.
Under the terms of the agreement, Yourgene will offer its NIPT products on Thermo's NGS instruments in Southeast Asia and pay off its debts to Thermo.
The company, which changed its name from Premaitha Health last month, saw a 73 percent increase in testing volumes during the first half of fiscal year 2018.
Quest Diagnostics and Oxford Immunotec Global announced this week that Quest has completed its previously announced acquisition of Oxford Immunotec's US laboratory services business.
Quest Diagnostics this week announced it is acquiring the outreach laboratory services of Marin General Hospital located in Greenbrae, California.